Post by Mediamedic

🎗️📊 Professor Oleg Gluz, Prof. Dr. med: Refining Chemotherapy Through “Addition and Subtraction” for High-Risk HR+/HER2− Breast Cancer As precision medicine continues to reshape breast cancer care, optimizing chemotherapy strategies for biologically high-risk HR-positive/HER2-negative breast cancer remains a major clinical challenge. At a recent academic conference, Professor Oleg Gluz of the West German Study Group (WSG) presented pooled analyses from the WSG ADAPT-HR+/HER2− and PlanB studies, offering important insights into treatment personalization. 📖 Read more to explore Professor Gluz’s interpretation of the WSG pooled analysis, the evolving role of precision chemotherapy in high-risk HR+/HER2− breast cancer, and how personalized treatment strategies are reshaping clinical decision-making. #OlegGluz #BreastCancer #HRPositiveBreastCancer #HER2Negative #PrecisionMedicine #Chemotherapy #WSG #PlanBStudy #ADAPTStudy #Oncology